Fundraising for R&D and domestic and overseas business expansion through stock acquisition rights and similar instruments
First written in FY2017. 5 of 6 entries say "Advanced", first in FY2018. Latest entry: FY2019.
The whole theme swung hardest in 2020: 1 of 10 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2019AdvancedAnnual report
「Cash provided by financing activities was ¥3,012 million. This was mainly attributable to ¥2,990 million in proceeds from the issuance of shares through the exercise of stock acquisition rights.」
The exercise of stock acquisition rights and other instruments used to fund research and development and domestic and overseas business expansion was completed, materializing as ¥2,990 million in proceeds from the issuance of shares. - FY2019-Q3AdvancedAnnual report
「Net assets were ¥9,522 million, an increase of ¥4,018 million from the end of the previous consolidated fiscal year. This was mainly attributable to the recognition of ¥1,895 million in capital stock and ¥1,893 million in capital surplus through the exercise of stock acquisition rights, including the exercise of rights attached to unsecured convertible bond-type bonds with stock acquisition rights.」
Funding through the exercise of stock acquisition rights and other instruments materialized as increases of ¥1,895 million in capital stock and ¥1,893 million in capital surplus. - FY2019-Q2AdvancedAnnual report
「Cash provided by financing activities was ¥2,992 million, compared with ¥150 million in the same quarter of the previous year. This was mainly attributable to ¥2,990 million in proceeds from the issuance of shares through the exercise of stock acquisition rights.」
Funding for research and development and domestic and overseas business expansion through the exercise of stock acquisition rights and other instruments materialized during the quarter as ¥2,990 million in proceeds from the issuance of shares. - FY2019-Q1AdvancedAnnual report
「During the cumulative first quarter, capital stock increased by ¥1,719.116 million and capital reserves increased by ¥1,717.632 million in connection with the issuance of new shares upon the exercise of stock acquisition rights, including the exercise of rights attached to unsecured convertible bond-type bonds with stock acquisition rights.」
Funding for research and development and domestic and overseas business expansion through the exercise of stock acquisition rights and other instruments materialized in the first quarter as increases of ¥1,719.116 million in capital stock and ¥1,717.632 million in capital reserves. - FY2018AdvancedAnnual report
「Decrease in convertible bond-type bonds with stock acquisition rights: ¥770.000 million” “Type and number of shares issued: common shares, 658,119 shares” “Type and number of shares issued: common shares, 1,484,000 shares」
The convertible bond-type bonds with stock acquisition rights and stock acquisition rights issued as a means of funding research and development and domestic and overseas business expansion were exercised after the end of the fiscal year, making the funding concrete. - FY2017First statedAnnual report
「The group plans to raise funds through the exercise of its First Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights and Third Stock Acquisition Rights, among others, to strengthen research and development activities and accelerate business expansion in Japan and overseas.」
The company positions the exercise of bonds with stock acquisition rights and stock acquisition rights as a means of raising funds to strengthen research and development and accelerate domestic and overseas business expansion.